ARTICLE | Clinical News
Prothena sees potential path forward for amyloidosis candidate
April 26, 2019 8:00 PM UTC
Prothena said it will explore business development opportunities that could lead to further clinical investigation of amyloid light-chain (AL) amyloidosis candidate birtamimab (NEOD001) after post hoc analyses of the Phase III VITAL trial showed a potential survival benefit in a subgroup of patients at highest risk for early mortality.
Prothena Corp. plc (NASDAQ:PRTA) said a post hoc analysis of all-cause mortality by Mayo Stage showed an HR of 0.54 (95% CI: 0.27, 1.08, p=0.079) in favor of birtamimab vs. placebo among 77 AL amyloidosis patients categorized as Mayo Stage IV...
BCIQ Company Profiles
BCIQ Target Profiles